A 62-Year-Old Women With Persistent Severe Asthma, Skin Rash, and Eosinophilia

Montelukast attenuates interleukin IL-1β-induced oxidative stress and apoptosis in chondrocytes by inhibiting CYSLTR1 (Cysteinyl Leukotriene Receptor 1) and activating KLF2 (Kruppel Like Factor 2)

“…Montelukast is also well documented as a critical anti-inflammatory modulator widely used for asthma and allergic rhinitis treatment, and its anti-oxidant properties in multiple tissues and organs cannot be overlooked [14,15]. Furthermore, montelukast treatment protects the liver against LPS-induced oxidative damage [16].…”

“…It is a potent selective antagonist of leukotriene D4 at the cysteinyl leukotriene (cysLT) type 1 receptor, which is presented in human respiratory epithelial cells and is produced by cells including macrophages and eosinophils [ 12 , 13 ]. Montelukast is also well documented as a critical anti-inflammatory modulator widely used for asthma and allergic rhinitis treatment, and its anti-oxidant properties in multiple tissues and organs cannot be overlooked [ 14 , 15 ]. Furthermore, montelukast treatment protects the liver against LPS-induced oxidative damage [ 16 ].…”